News

AddToAny

Google+ Facebook Twitter Twitter

Leukaemia inequality still an issue

Although global inequalities in survival from childhood leukaemia have narrowed, they still persist, a new study shows.

The research in The Lancet Haematology says that five-year survival in some countries is nearly twice as high as in others. Five-year survival for acute lymphoblastic leukaemia in Germany was 92%, compared with 52% in Colombia for children diagnosed in 2005-09. 

The authors used individual patient data for almost 90,000 children, provided by 198 cancer registries in 53 countries. 

“There is room for improvement in the management of childhood leukaemia in many countries,” said 
lead author Dr Audrey Bonaventure of the London School of Hygiene & Tropical Medicine. “These findings show the extent of worldwide inequalities in access to optimal healthcare for children with cancer.”

bit.ly/BS_JuneNews7

Related Articles

girl computer_CREDIT_shutterstock-58872785

Gamification in biomedical science education

Senior Lecturer in Biomedical Science Jen May outlines the successful implementation of scenario-based learning software.

web_blood-testing_credit_istock-1384651794.png

SPONSORED: The power of automated gel-based ID-cards in routine immunohematology workflows

Immuno-haematology assays are pivotal to the carrying out of blood grouping, antibody screening and transfusions, and represent a critically time-dependent stage in the patient management pathway.

Technician holding a blood sample ready for testing with other human medical samples in the background.-Image credit - Science-Photo-Library-f0243823

Machine learning tool to detect cancer via liquid biopsy

US researchers have developed and tested an innovative machine-learning approach that could one day enable the earlier detection of cancer in patients by using smaller blood draws.

multiple myelomatosis-CREDIT-Science Photo Library-m132099

IBMS research grants

We look at the work of Dr Mosavar Farahani who received an IBMS Research Grant in 2023 to help fund her work on disease progression and skeletal complications in multiple myeloma.

Top